Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 209 publications
Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.
Journal: Internal medicine (Tokyo, Japan)
Published: September 24, 2025
Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report.
Journal: Case reports in oncological medicine
Published: June 20, 2025
The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.
Journal: Translational lung cancer research
Published: June 17, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Journal: Nature reviews. Clinical oncology
Published: June 12, 2025
PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: May 15, 2025
Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination.
Journal: Respirology case reports
Published: May 07, 2025
Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer.
Journal: Cancer treatment reviews
Published: May 01, 2025
Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum.
Journal: Reports (MDPI)
Published: April 03, 2025
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system.
Journal: Expert opinion on drug safety
Published: April 03, 2025
Last Updated: 10/31/2025